Exchange: NYSEMkt·Updated 07:36 AM EDT
VNRX logo

VNRX VolitionRX Ltd

$0.3687
$0.0255
(6.47%)
Pre-Market
Prev Close $0.3942
Reported EarningsAug 13
Mkt Cap$5.92M
Vol173,591.00

About VNRX

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
83

Extremely Bullish Sentiment

How do you feel about VNRX?

Advertisement|Remove ads.